Based on the Autolus Therapeutics Ltd stock forecast from 4 analysts, the average analyst target price for Autolus Therapeutics Ltd is USD 10.10 over the next 12 months. Autolus Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Autolus Therapeutics Ltd is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Autolus Therapeutics Ltd’s stock price was USD 2.94. Autolus Therapeutics Ltd’s stock price has changed by -4.55% over the past week, -33.78% over the past month and -34.38% over the last year.
No recent analyst target price found for Autolus Therapeutics Ltd
No recent average analyst rating found for Autolus Therapeutics Ltd
Company Overview Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP Read Less
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational t...Read More
Frequently Asked Questions About Autolus Therapeutics Ltd (AUTL) Stock
Based on ratings from 4 analysts Autolus Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUTL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AUTL is USD 10.10 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 7.6.
Unfortunately we do not have enough data on AUTL's stock to indicate if its overvalued.
The last closing price of AUTL's stock was USD 2.94.
The most recent market capitalization for AUTL is USD 0.78B.
Based on targets from 4 analysts, the average taret price for AUTL is projected at USD 10.10 over the next 12 months.
This means that AUTL's stock price may go up by +243.54% over the next 12 months.
We can't find any ETFs which contains Autolus Therapeutics Ltd's stock.
As per our most recent records Autolus Therapeutics Ltd has 463 Employees.
Autolus Therapeutics Ltd's registered address is The MediaWorks, London, United Kingdom, W12 7FP.
You can get more information about it from Autolus Therapeutics Ltd's website at https://www.autolus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Autolus Therapeutics Ltd (AUTL) Stock
Based on ratings from 4 analysts Autolus Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on AUTL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AUTL is USD 10.10 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 7.6.
Unfortunately we do not have enough data on AUTL's stock to indicate if its overvalued.
The last closing price of AUTL's stock was USD 2.94.
The most recent market capitalization for AUTL is USD 0.78B.
Based on targets from 4 analysts, the average taret price for AUTL is projected at USD 10.10 over the next 12 months.
This means that AUTL's stock price may go up by +243.54% over the next 12 months.
We can't find any ETFs which contains Autolus Therapeutics Ltd's stock.
As per our most recent records Autolus Therapeutics Ltd has 463 Employees.
Autolus Therapeutics Ltd's registered address is The MediaWorks, London, United Kingdom, W12 7FP.
You can get more information about it from Autolus Therapeutics Ltd's website at https://www.autolus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AUTL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
